RE245

RE245, or RE-245, is a non-hallucinogenic psychoplastogen which is under development for the treatment of psychiatric disorders.^[1]^[2]^[3]^[4]^[5] It is taken orally.^[1] The drug acts as a serotonin receptor modulator, including of the serotonin 5-HT_2A receptor, and is said to have psychoplastogenic effects.^[1]^[2]^[3]^[4] It is being developed by Reunion Neuroscience.^[1]^[2]^[3]^[4]^[5] As of August 2025, RE245 is in the preclinical research stage of development.^[1]^[2]^[3]^[4]^[5] An Investigational New Drug (IND) application to allow for phase 1 clinical trials is planned to be submitted in 2026, with these studies expected to start in 2027.^[1]^[4] The chemical structure of RE245 does not yet appear to have been disclosed.^[1]

Other namesRE-245

Routes of
administrationOral^[1]

Drug classSerotonin receptor modulator; Non-hallucinogenic serotonin 5-HT_2A receptor agonist; Psychoplastogen

Quick facts Clinical data, Other names ...

RE245
Clinical data
Other names	RE-245
Routes of administration	Oral^[1]
Drug class	Serotonin receptor modulator; Non-hallucinogenic serotonin 5-HT_2A receptor agonist; Psychoplastogen

References

[1]
"RE 245". AdisInsight. 8 January 2025. Retrieved 24 October 2025.
[2]
"Delving into the Latest Updates on RE245 with Synapse". Synapse. 18 October 2025. Retrieved 24 October 2025.
[3]
Mayes G (27 March 2025). "Unlocking the Potential of Psychedelics for Postpartum Depression". Pharma's Almanac. Beyond RE104, we also have a preclinical asset, RE245, which represents the next evolution of our platform. RE245 is a non-psychedelic serotonergic neuroplastogen designed to provide therapeutic mental health benefits without inducing hallucinations. The goal is to create an oral 5-HT2A agonist that can offer the neuroplastic benefits of psychedelics without the experiential effects, potentially making it suitable for chronic outpatient use. This is an ambitious area of research; many companies are trying to develop non-hallucinogenic psychedelics, but nobody has fully proven the concept yet. Still, our chief scientific officer, Dr. Nathan Bryson, who led the development of RE104, is now driving this project forward. While still in early development, RE245 could represent the future of serotonergic neuroplasticity-based treatments.
[4]
Haichin M (28 August 2025). "Psychedelic: Exclusive talk with biopharma company Reunion Neuroscience". TipRanks Financial. Retrieved 24 October 2025. NON-PSYCHEDELIC RE245: Reunion has also advanced lead candidate RE245, a discovery-stage, non-psychedelic asset, for application in chronic treatment paradigms and plans to file an Investigational New Drug application in 2026. [...] As part of Reunion's non-psychedelic research, the company built a whole library of molecules, found certain safety aspects and designed RE245, the CSO said. [...] We are currently in the throes of preclinical assessment of the molecule to build our safety package that we would present to the FDA toward the end of 2026, so we can do some initial studies in humans in 2027."
[5]
"Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 24 October 2025.

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

See also

References

Related Articles